// STATE LEGISLATION TRACKER

Illinois SB 3146: 340B PRICING PROGRAM REPORT

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Illinois
Bill: SB 3146
Session: 104th
Filed: 2026-02-02
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Illinois SB3146 would create reporting rules for entities using the federal 340B drug pricing program and require public aggregate reports. Based on the title, synopsis, and status, it does not directly address compounded peptides, off-label prescribing, telehealth, naturopathic or NP scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct change to peptide prescribing or access
No apparent change to 503A or 503B compounding rules
No telehealth, NP, or naturopathic scope expansion
Applies to 340B drug program reporting, not peptide clinics
Peptide users should not expect practical changes from this bill

What to Watch For

Note Watch for amendments that could broaden the bill beyond 340B reporting into pharmacy or drug access rules.

Note Public 340B reports could add pricing transparency, but not specifically for compounded peptides.

Note Manufacturer information requests may matter to 340B entities, not typical peptide prescribers or patients.

Where the Bill Stands

The bill was re-referred to the Senate Assignments Committee on March 27, 2026, so it has not passed a chamber.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws